Flag of the European Union EU Clinical Trials Register Help

Clinical trials for T-cell lymphoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    256 result(s) found for: T-cell lymphoma. Displaying page 1 of 13.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-023040-32 Sponsor Protocol Number: ROMI-ADVM-004 Start Date*: 2011-05-05
    Sponsor Name:Celgene Corporation
    Full Title: A phase IV, Open-Label, Single-Arm ROLLOVER STUDY FOR SUBJECTS WHO PARTICIPATED IN OTHER ROMIDEPSIN PROTOCOLS. Estudio de extensión de fase IV, abierto, de un solo brazo para pacientes que hayan p...
    Medical condition: Rollover study supporting all indications from prior Romidepsin protocols eligible for participation in this study. Estudio de extensión que recoge todas las indicaciones de protocolos anteriores d...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001414 Adult T-cell lymphomas/leukaemias HLT
    12.1 10042971 T-cell lymphoma LLT
    12.1 10042979 T-cell lymphoma recurrent LLT
    12.1 10042980 T-cell lymphoma refractory LLT
    12.1 10042981 T-cell lymphoma stage I LLT
    12.1 10042982 T-cell lymphoma stage II LLT
    12.1 10042983 T-cell lymphoma stage III LLT
    12.1 10042984 T-cell lymphoma stage IV LLT
    12.1 10002450 Angioimmunoblastic T-cell lymphomas HLT
    12.1 10022704 Intestinal T-cell lymphomas HLT
    12.1 10034622 Peripheral T-cell lymphomas NEC HLT
    12.1 10042988 T-cell unclassifiable lymphomas HLT
    12.1 10001414 Adult T-cell lymphomas/leukaemias HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-003526-80 Sponsor Protocol Number: CLSG-PTCL-CHEPA Start Date*: 2021-12-16
    Sponsor Name:Kooperativní lymfomová skupina, z.s.
    Full Title: A Phase II Open Label Study of Brentuximab Vedotin in combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas.
    Medical condition: Peripheral T-cell lymphomas (PTCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002450 Angioimmunoblastic T-cell lymphomas HLT
    20.0 100000004851 10001414 Adult T-cell lymphomas/leukaemias HLT
    20.0 100000004851 10022704 Intestinal T-cell lymphomas HLT
    20.0 100000004851 10034622 Peripheral T-cell lymphomas NEC HLT
    21.0 100000004864 10002451 Angioimmunoblastic T-cell lymphoma NOS LLT
    21.0 100000004864 10001415 Adult T-cell lymphoma/leukaemia NOS LLT
    21.1 100000004864 10076434 Hepatosplenic gamma-delta T-cell lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004146-18 Sponsor Protocol Number: CCR3549 Start Date*: 2011-11-09
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) versus gemcitabine, cisplatin and methyl prednisolone (GEM-P) in the first line treatment Of T-cell Lymphoma, a multicentre rando...
    Medical condition: T-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10001414 Adult T-cell lymphomas/leukaemias HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-003983-28 Sponsor Protocol Number: SGN35-028 Start Date*: 2020-11-27
    Sponsor Name:SEAGEN INC.
    Full Title: A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classic Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma...
    Medical condition: - classic Hodgkin lymphoma (cHL) - Systemic anaplastic large cell lymphoma (sALCL) - CD30-expressing peripheral T cell lymphoma (PTCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073478 Anaplastic large-cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020328 Hodgkin's lymphoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034623 Peripheral T-cell lymphoma unspecified PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034624 Peripheral T-cell lymphoma unspecified NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001412 Adult T-cell leukemia-lymphoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065855 Extranodal NK/T-cell lymphoma, nasal type LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073481 Enteropathy-associated T-cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022703 Intestinal T-cell lymphoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061232 Lymphoproliferative disorder PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066957 Hepatosplenic T-cell lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002449 Angioimmunoblastic T-cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042971 T-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003982-17 Sponsor Protocol Number: SGN35-015 Start Date*: 2020-10-21
    Sponsor Name:SEATTLE GENETICS, INC.
    Full Title: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant...
    Medical condition: • Hodgkin lymphoma (HL) • CD30-expressing peripheral T-cell lymphoma (PTCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020328 Hodgkin's lymphoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034623 Peripheral T-cell lymphoma unspecified PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034624 Peripheral T-cell lymphoma unspecified NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073478 Anaplastic large-cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001412 Adult T-cell leukemia-lymphoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065855 Extranodal NK/T-cell lymphoma, nasal type LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073481 Enteropathy-associated T-cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022703 Intestinal T-cell lymphoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061232 Lymphoproliferative disorder PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066957 Hepatosplenic T-cell lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002449 Angioimmunoblastic T-cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042971 T-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006229-23 Sponsor Protocol Number: PTCLS-IDE Start Date*: 2022-04-07
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas.
    Medical condition: peripheral T Cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10003622 ATLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-000243-23 Sponsor Protocol Number: Hx-CD4-109 Start Date*: 2004-08-03
    Sponsor Name:Genmab A/S
    Full Title: An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with refractory or relapsed Non-Cutaneous CD4+ T-Cell Lymphoma
    Medical condition: The mature non-cutaneous T-cell lymphomas expressing the CD4 molecule are the object of this protocol. 1.Peripheral T-cell lymphoma (PTCL) unspecified 2.Angioimmunnoblastic T-cell lymphoma 3.Anapl...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10042971 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-022036-36 Sponsor Protocol Number: A8641014 Start Date*: 2011-02-15
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 1 trial of pf‑03084014 in patients with advanced solid tumor malignancy and t‑cell acute lymphoblastic leukemia/lymphoblastic lymphoma
    Medical condition: advanced solid tumor malignancies or relapsed or refractory acute T-cell lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066110 LLT
    9.1 10065252 LLT
    9.1 10065923 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004234-33 Sponsor Protocol Number: PTCL-06 Start Date*: 2006-10-06
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Intensive chemo-immunotherapy as first-line treatment in adult patients with peripheral T-cell Lymphoma PTCL
    Medical condition: Non Hodgkin peripheral T-cell lymphomas
    Disease: Version SOC Term Classification Code Term Level
    6.1 10034623 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024215-14 Sponsor Protocol Number: C25001 Start Date*: 2012-11-06
    Sponsor Name:Millennium Pharmaceuticals, Inc
    Full Title: A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
    Medical condition: CD30-Positive Cutaneous T-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10011677 Cutaneous T-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) ES (Completed) DE (Completed) AT (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-004675-11 Sponsor Protocol Number: 133/2004/U Start Date*: 2004-09-14
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Clinical trial of phase II for the a front line treatment of the non-Hodgkin lymphomas of derivation lymphocyte T Gemcitabine and Oxaliplatin GEMOX
    Medical condition: Non Hodgkin s disease of lymphocyte T derivation
    Disease: Version SOC Term Classification Code Term Level
    6.1 10025321 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-003879-12 Sponsor Protocol Number: MK-0683 042-00 Start Date*: 2007-03-23
    Sponsor Name:Merck & Co., Inc.
    Full Title: Compassionate Use of Vorinostat (MK-0683) for the Treatment of Patients with Advanced Cutaneous T-Cell Lymphoma
    Medical condition: Cutaneous T-cell lymphoma (CTCL)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011677 Cutaneous T-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) DK (Completed) FI (Completed) SI (Completed) IT (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002336-74 Sponsor Protocol Number: SGN35-032 Start Date*: 2020-12-08
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression
    Medical condition: Non-sALCL PTCL and CD30 expression <10%
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10034624 Peripheral T-cell lymphoma unspecified NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-000306-36 Sponsor Protocol Number: 2008-000306-36 Start Date*: 2009-04-16
    Sponsor Name:Region Skåne
    Full Title: Nexavar in Relapsed Peripheral T-cell Non-Hodgkins Lymphoma
    Medical condition: Patients >18 years with relapsed or resitant peripheral T-cell lymphoma, defined as having progressed on 1st or 2nd line therapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042973 T-cell lymphoma NOS recurrent LLT
    9.1 10042974 T-cell lymphoma NOS refractory LLT
    9.1 10042979 T-cell lymphoma recurrent LLT
    9.1 10042980 T-cell lymphoma refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006130-17 Sponsor Protocol Number: NordicLymphomaGroup Start Date*: 2007-09-05
    Sponsor Name:Aarhus University Hospital
    Full Title: ACT-1 (younger patients) A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP v...
    Medical condition: Patients 18 - 65 years old with newly diagnosed non-cutanous, non leukemic Peripheral T- cell lymphoma, except alk-protein positive and negative anaplastic large cell lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042971 T-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) FI (Completed) PT (Completed) DE (Completed) SE (Completed) NL (Completed) AT (Completed) PL (Completed) CZ (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001164-24 Sponsor Protocol Number: PTCL01 Start Date*: 2006-11-14
    Sponsor Name:G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
    Full Title: MAINTENANCE TREATMENT WITH ALEMTUZUMAB Campath AS AN ALTERNATIVE TO ALLOGENIC TRANSPLANTATION IN PATIENTS WITHOUT COMPATIBLE DONOR IN PATIENTS WITH PERIPHERAL T CELL LYMPHOMA
    Medical condition: patients with Perpheral T cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10025321 HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022230-81 Sponsor Protocol Number: PDX-017 Start Date*: 2011-04-05
    Sponsor Name:Allos Therapeutics, Inc.
    Full Title: A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients with Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Fo...
    Medical condition: Patients with previously undiagnosed peripheral T-cell lymphoma who have achieved an objective response following initial treatment with CHOP-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034623 Peripheral T-cell lymphoma unspecified PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) IE (Completed) ES (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001396-11 Sponsor Protocol Number: PXD101-CLN-6 Start Date*: 2007-09-18
    Sponsor Name:CuraGen Corporation
    Full Title: A Phase II Clinical Trial of PXD101 in Patients with Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
    Medical condition: T-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042971 T-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004516-51 Sponsor Protocol Number: GEN112 Start Date*: 2006-11-20
    Sponsor Name:Genmab A/S
    Full Title: A multicentre open-label, dose-escalation, trial of zanolimumab in combination with CHOP chemotherapy in subjects with CD4 positive non-cutaneous peripheral T-Cell Lymphoma with nodal involvement
    Medical condition: CD4 positive non-cutaneous peripheral T-Cell Lymphoma with nodal involvement
    Disease: Version SOC Term Classification Code Term Level
    8.1 10034624 Peripheral T-cell lymphoma unspecified NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000433-30 Sponsor Protocol Number: UCL/17/0053 Start Date*: 2018-05-23
    Sponsor Name:University College London
    Full Title: Phase II Trial of Pembrolizumab and Radiotherapy in Cutaneous T cell lymphoma
    Medical condition: Cutaneous T cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10011677 Cutaneous T-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 31 22:49:38 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA